Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective
- PMID: 35822854
- DOI: 10.1093/infdis/jiac252
Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective
Keywords: RSV prevention; costs; epidemiology; hospitalization; vaccines.
Conflict of interest statement
Potential conflicts of interest . The author is a member of the independent external International Scientific Advisory Group for RESCEU. The author reports grants and consulting fees to the institution from Merck and Pfizer; grants to the institution from Astra Zeneca, Roche Pharmaceuticals, and Johnson & Johnson; consulting fees to the institution from Sanofi Pasteur, Cidara Therapeutics, Adiago Therapeutics, and Nuance Pharmaceuticals; manuscript editorial writing support from Pfizer and Astra Zeneca; support for attending a meeting from Astra Zeneca; and participation on data and safety monitoring boards for AbbVie, GlaxoSmithKline, and the Bill & Melinda Gates Foundation, all outside the submitted work. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical